If young girls were dying or becoming permanently disabled after receiving a vaccine approved by the FDA, wouldn’t you want the agency to pull the vaccine off the shelves and conduct more research?

That’s exactly the situation we’re in today. But unfortunately calls to the FDA to do something about it have fallen on deaf ears — even as the situation appears to worsen.

Judicial Watch received yet another batch of documents from the U.S. Food and Drug Administration (FDA) detailing reports of adverse reactions to the vaccination for human papillomavirus (HPV), Gardasil.

These most recent adverse reactions include 16 new deaths (including four suicides) between May 2009 and September 2010. The FDA also produced 789 “serious” reports, with 213 cases resulting in permanent disability and 25 resulting in a diagnosis of Guillain Barre Syndrome.

Here are a few excerpts from the documents uncovered by Judicial Watch:


One mother of a 13-year old girl, who died 37 days after receiving the vaccination, noted in a report: “I first declined getting her the vaccination but her doctor ensured me that it was safe…” After her daughter complained of a severe headache, no feeling in her foot and a tingling feeling in her leg, a doctor’s appointment was set for October 23, 2009. “My daughter never made it to Oct[ober] 23rd, which is also her birthday,” the mother noted. “She passed on Oct[ober] 17th, I found her cold unresponsive in her room at 7am….”

To say Gardasil has a suspect safety record is a big understatement. These reports are troubling and show that the FDA and other public health authorities may be asleep at the switch. In the meantime, the public relations push for Gardasil by Merck and by politicians on Capitol Hill continues. No one should be pushing this vaccine for young children.

By the way, if you want to check out all of the FDA documents previously uncovered by Judicial Watch, or our special report entitled “Examining the FDA’s HPV Vaccine Records: Detailing the Approval Process, Side-Effects, Safety Concerns & Marketing Practices of a Large Scale Health Experiment,” click here.